Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of cisplatin in human colon adenocarcinoma cells: Differential caspase activation as a basis for interaction

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3241-3246

  Vasilevskaya, Irina A ^a,b   Rakitina, Tatiana V ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; CASPASE; CASPASE 3; CASPASE 8; CISPLATIN; DRUG DERIVATIVE; GELDANAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADENOCARCINOMA HCT116 CELL; ADENOCARCINOMA HT29 CELL; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL SURVIVAL; COLON ADENOCARCINOMA; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C JUN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; BENZOQUINONES; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CISPLATIN; COLONIC NEOPLASMS; DNA FRAGMENTATION; DNA REPAIR; ENZYME ACTIVATION; GENES, P53; HUMANS; LACTAMS, MACROCYCLIC; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; QUINONES; RIFABUTIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038069088     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
2. Gibbs, J. B. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Investig., 105: 9-13, 2000.
3. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000.
4. Neckers, L. Hsp90 inhibitors as novel chemotherapeutic agents. Trends Mol. Med., 8: S55-S61, 2002.
5. Workman, P., and Maloney, A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther., 2: 3-24, 2002.
6. Uehara, Y., Myrakawi, Y., Mizuno, S., and Kawai, S. Inhibition of transforming activity of tyrosin kinase oncogenes by herbimycin A. Virology. 164: 294-298, 1988.
7. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. Inhibition of heat-shock protein Hsp90-pp6βv-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
8. Richter, K., and Buchner, J. Hsp90: Chaperoning signal transduction. J. Cell. Physiol., 188: 281-290, 2001.
9. Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A. J., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H. J., Schulle, T. W., Sausville, E., Neckers, L. M., and Toft, D. O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem., 272: 23843-23850, 1997.
10. Whitesell, L., Sutphin, P., Wen, G. A., Schulte, T., Blagosklonny, M. V., and Neckers, L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by proteasome in vivo. Oncogene, 14: 2809-2816, 1997.
11. Schulte, T. W., Won, G. A., and Neckers, L. M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun., 239: 655-659, 1997.
12. erB2, Raf- 1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother. Pharmacol., 40: 60-64, 1997.
13. Supko, J. G., Hickman, R. L., Grever, M. R., and Malspeis, L. Preclinical pharmacological evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol., 36: 305-315, 1995.
14. Schulte, T., and Neckers, L. The benzoquinone ansamycin 17-allylamino-17-demethoxy-geldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
15. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., and Workman, P. DT-Diaphorase expression and tumor cells sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (Bethesda), 91: 1940-1949, 1999.
16. Hostein, I., Robertson, D., DiStefano, F., Workman, P., and Clarke, P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res., 61: 4003-4009, 2001.
17. Yang, J., Yang, J-M., Iannone, M., Shih, J., Lin, Y., and Hait, W. N. Disruption of the EF-2 kiaase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by Geldanamycin. Cancer Res., 61: 4010-4016, 2001.
18. Münster, P. N., Srethapakdi, M., Moasser, M. M., and Rosen, N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res., 61: 2945-2952, 2001.
19. Wilson, R. H., Takimoto, C. H., Agnew. E. B., Morrison, G., Grollman, F., Thomas, R. R., Saif, M. W., Hopkins, J., Allegra, C., Grochow, L., Szabo, E., Hamilton, J. M., Monhan B. P., Neckers, L., and Grem, J. L. Phase I pharmacological study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 82a, 2001.
20. Münster, P. N., Tong, W., Schwartz, L., Larson, S., Keneson, K., De La Cruz, A., Rosen, N., and Scher, H. Phase 1 trial of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 83a, 2001.
21. Nguyen, D. M., Logang, D., Chen, A., Stewart, J. H., IV, Tabibi, E., and Schrump, D. S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann. Thorac. Surg., 72: 371-379, 2001.
22. Münster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
23. Reinert, K. E. Anthracycline-binding induced DNA stiffening, bending and elongation: stereochemical implications from viscometric investigations. Nucleic Acid Res., 11: 3411-3440, 1983.
24. Rosenberg, B. Platinim complexes for the treatment of cancer: why the search goes on. In: B. Lippert (ed.), Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, p. 3. Zurich, Switzerland: Verlag Helvetica Chimica Acta, 1999.
25. O'Dwyer, P., Stevenson, J., and Johnson, S. Clinical status of cisplatin, carboplatin and other platinum-based antitumor drugs. In: B. Lippert (ed.), Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, p. 31. Zurich, Switzerland: Verlag Helvetica Chimica Acta, 1999.
26. Johnson, S. W., Stevenson, P. J., and O'Dwyer, P. J. Cisplatin and its analogues. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.). Cancer: Principles and Practice of Oncology, Ed. 6, pp. 377-388. Philadelphia: Lippincott, Williams & Wilkins, 2001.
27. Gonzales, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. Is cisplatin-induced death always produced by apoptosis? Mol. Pharmacol., 59: 657-663, 2001.
28. Fulda, S., Los, M., Friesen, C., and Debatin, K-M. Chemosensitivity of solid tumor cells in vitro related to activation of the CD95 system. Int. J. Cancer, 76: 105-114, 1998.
29. Kojima, H., Eodo, K., Moriyama, H., Tanaka, Y., Alnemri, E. S., Slapak, C. A., Teicher, B., Kufe, D., and Datta, R. Abrogation of mitochondrial cytochrome C release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem., 273: 16647-16650, 1998.
30. 2-M when it is transactivation defective. EMBO J., 14: 4994-5005, 1995.
31. Seki, T., Ohba, N., Makino, R., Funatomi, H., and Mitamura, K. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene. Anticancer Res., 21: 1919-1924, 2001.
32. Persons, D. L., Yazlovitskaya, E. M., Cui, W., and Pelling, J. C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res., 5: 1007-1014, 1999.
33. Wang, X., Martindale, J. L., and Holbrook, N. J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem., 275: 39435-39443, 2000.
34. Sanchez-Perez, I., Murguia, J. R., and Perona, R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene, 16: 533-540, 1998.
35. Hayakawa, J., Ohmich, M., Kurachi, H., Ikegami, H., Kimura, A., Matsuoka, T., Jikihara, H., Mercola, D., and Murata, Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitized human ovarian cancer cell line. J. Biol. Chem., 274: 31648-31654, 1999.
36. Sanches-Prieto, R., Rojas, J. M., Taya, Y., and Gutkind, S. A role for p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res., 60: 2464-2472, 2000.
37. Vasilevskaya, I. A., and O'Dwyer, P. J. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res., 59: 3935-3940, 1999.
38. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
39. Tsai, C-M., Gazdar, A. F., Venzon, D. J., Steinberg, S. M., Dedrick, R. L., Mulshine, J. L., and Kramer, B. S. Lack of in vitro synergy between etoposide and cisdiammine-dichloroplatinum (II). Cancer Res., 49: 2390-2397, 1989.
40. Chou, T-C., Motzer, R. J., Tong, Y., and Bosl, G. J. Computerized quantification of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer. Inst. (Bethesda), 86: 1517-1524, 1994.
41. Liu, Y., and Kulesz-Martin, M. p53 protein at the huh of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis (Lond.), 22: 851-860, 2001.
42. Gjerset, R. A., Lebedeva, S., Haghigni, A. Turia, S. T., and Mercola, D. Inhibition of Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ., 10: 545-554, 1999.
43. Pan, B., Yao, K-S., Monia, B., Dean, N. M. McKay, R. A., Hamilton, T. C., and O'Dwyer, P. J. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem. Pharmacol., 63: 1699-1707, 2002.
44. Shaulian, E., and Katin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol., 4: E131-E136, 2002.
45. Nguen, D. M., Chen, A., Mixon, A., and Schrump, D. S. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxy-geldanamycin. J. Thorac. Cardiovasc. Surg., 118: 908-915, 1999.
46. Itoh, H., Ogura, M., Komatsuda, A., Wakui, H., Miura, A. B., and Tashima, Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J., 343: 697-703, 1999.
47. Marcu, M. G., Chadli, A., Bouhouche, I., Gatelli, M., and Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl-terminus of the chaperone. J. Biol. Chem., 275: 37181-37186, 2000.
48. Soti, C., Racz, A., and Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at C-terminal dOmain of Hsp90: N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem., 277: 7066-7075, 2002.
49. Jordan, P., and Carmo-Fonseca, M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci., 57: 1229-1235, 2000.
50. Münster, P. N., Marchion, D. C., Basso, A., and Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res., 62: 3132-3137, 2002.
51. Sano, M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology, 40: 947-953, 2001.
52. Chao, C. Saito, S., Kang, J., Anderson, C. W., Appella, E., and Xu, Y. p53 transcriptional activity is essential for p-53 dependent apoptosis following DNA damage. EMBO J., 19: 4967-4975, 2000.
53. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y. Dillehay, L., Williams, J. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999.
54. Ryan, K. M., and Voudsen, K. H. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol., 18: 3692-3698, 1998.
55. Aurelio, O. N., Kong, X-T., Gupta, S., and Stanbridge, E. J. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol., 20: 770-778, 2000.
56. Ferreira, C. G., Tolis, C., Span, S. W., Peters, G. J., van Lopik, T., Kummer, A. J., Pinedo, H. M., and Giaccone, G. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin. Cancer Res., 6: 203-212, 2000.
57. Micheau, O., Hammann, A., Solary, E., and Dimanche-Boitrel, M-T. STAT-1-independent up-regulation of procaspase -3 and -8 in cancer cells treated with cytotoxic drugs. Biochem. Biophys. Res. Commun., 256: 603-607, 1999.
58. Micheau, O., Solary, E., Hammann, A., and Dimanche-Boitrel, M-T. Fas ligandindependent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem., 274: 7987-7992, 1999.